New Horizon Health (“NHH”), a leading Chinese molecular diagnostic company focusing on early cancer detection, submitted its A1-filing for Hong Kong Stock Exchange IPO. On the business front, NHH’s flagship product, ColoClear (a non-invasive multi-target stool DNA test for colorectal cancer screening), has recently been approved by the China NMPA.

VMS led the Series C round financing of NHH and participated in its Series D round financing.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.